Pub. Date : 2020 Jul 31
PMID : 32578856
10 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | NLRP3 augmented resistance to gemcitabine in triple-negative breast cancer cells(TNBCC) via EMT/IL-1beta/Wnt/beta-catenin signaling pathway. | gemcitabine | NLR family pyrin domain containing 3 | Homo sapiens |
| 2 | We investigated the sensitivity to gemcitabine responsive to regulation of NLRP3 expression in TNBCC in different gemcitabine concentrations. | gemcitabine | NLR family pyrin domain containing 3 | Homo sapiens |
| 3 | We investigated the sensitivity to gemcitabine responsive to regulation of NLRP3 expression in TNBCC in different gemcitabine concentrations. | gemcitabine | NLR family pyrin domain containing 3 | Homo sapiens |
| 4 | Gemcitabine resistance was studied in GRC exposed to 0,1,3,5nm gemcitabine after GRC were treated with NLRP3 agonist NSS or antagonist CY-09. | gemcitabine | NLR family pyrin domain containing 3 | Homo sapiens |
| 5 | RESULTS: NLRP3 upregulation improved cell survival and reduced sensitivity to gemcitabine (P<0.05). | gemcitabine | NLR family pyrin domain containing 3 | Homo sapiens |
| 6 | NLRP3 upregulation added to resistance to gemcitabine in GRC(P<0.05). | gemcitabine | NLR family pyrin domain containing 3 | Homo sapiens |
| 7 | CONCLUSION: NLRP3 could enhance resistance to gemcitabine via IL-1beta/EMT/Wnt/beta-catenin signaling, which suggested that NLRP3 antagonist CY-09 might be incorporated into gemcitabine treatment for TNBC. | gemcitabine | NLR family pyrin domain containing 3 | Homo sapiens |
| 8 | CONCLUSION: NLRP3 could enhance resistance to gemcitabine via IL-1beta/EMT/Wnt/beta-catenin signaling, which suggested that NLRP3 antagonist CY-09 might be incorporated into gemcitabine treatment for TNBC. | gemcitabine | NLR family pyrin domain containing 3 | Homo sapiens |
| 9 | CONCLUSION: NLRP3 could enhance resistance to gemcitabine via IL-1beta/EMT/Wnt/beta-catenin signaling, which suggested that NLRP3 antagonist CY-09 might be incorporated into gemcitabine treatment for TNBC. | gemcitabine | NLR family pyrin domain containing 3 | Homo sapiens |
| 10 | CONCLUSION: NLRP3 could enhance resistance to gemcitabine via IL-1beta/EMT/Wnt/beta-catenin signaling, which suggested that NLRP3 antagonist CY-09 might be incorporated into gemcitabine treatment for TNBC. | gemcitabine | NLR family pyrin domain containing 3 | Homo sapiens |